Filing Flows › Health Care › Whitehawk Therapeutics (WHWK)
Whitehawk Therapeutics (WHWK) earnings and revenue breakdown
Latest: Q1 2025 · 10-Q filed May 8, 2025 · Whitehawk Therapeutics (WHWK) Q1 2025 earnings results →
Q1 2025 Revenue up 34% year over year to $7.1M · operating margin -213.0%
Whitehawk Therapeutics made $7.1M in Q1 2025 (+34% Y/Y). Operating margin -213.0%, net earnings $73.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 8, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $7.1M in Q1 2025, up 33% year over year and down 1% from the previous quarter.
Operating costs exceeded revenue by $15.2M, an operating margin of -213.0%. Total costs fell 10% while revenue rose 33%. The fastest-growing cost line was SG&A (+21%). Net earnings were $73.0M. The effective tax rate was 0.0%. Non-operating items added $88.2M, 121% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$11.9M. Non-cash charges added back $57K of depreciation and $1.7M of share-based compensation. Working capital and other items used $86.6M. Capital expenditures of $551K exceeded it, leaving free cash flow of −$12.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2025 | 10-Q | May 8, 2025 | $7.1M | +34% | -213.0% | $73.0M | −$11.9M |
| Q4 2024 | 10-K | Mar 28, 2025 | $7.2M | +14% | -261.8% | −$18.3M | −$15.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Whitehawk Therapeutics
We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to approval, launch, and commercialization. In December 2024, we entered into an intellectual property license agreement (the “WuXi License Agreement”) with WuXi Biologics (Shanghai FX) Co., Ltd. (“WuXi Biologics”) for the development and global commercialization of a portfolio of three next generation antibody drug conjugates (“ADCs”) targeting clinically validated, broadly overexpressed tumor antigens in high potential cancer indications with significant unmet need.
In its own words, from its 10-K, filed Mar 12, 2026.
Whitehawk Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +34% against the peers' median +10%. Operating margin: -213.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| WHWK Whitehawk Therapeutics | Q1 2025 | $7.1M | +34% | -213.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Whitehawk Therapeutics 10-Q on SEC EDGAR · CIK 1422142 · Pharmaceutical Preparations
13F: who owns WHWK and who is buying
More on WHWK
- How Whitehawk Therapeutics makes money: revenue by segment
- Whitehawk Therapeutics next earnings date and what analysts expect
- Whitehawk Therapeutics stock forecast, price target and fair value
- Who owns Whitehawk Therapeutics stock: holders, funds and Congress trades
- Whitehawk Therapeutics recalls, complaints and regulation
History
Every quarter: Q1 2025 results · Q4 2024 results